Needham & Company Starts Sage Therapeutics (SAGE) at Buy, Adding to Conviction List
Tweet Send to a Friend
Needham & Company analyst Ami Fadia initiates coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE